跳至主要内容
临床试验/ISRCTN23314770
ISRCTN23314770已完成未知

A randomised, double-blinded, placebo-controlled trial using cardiovascular magnetic resonance (CMR) scanning to assess remodelling and regression of fibrosis in cardiomyopathy with eplerenone

Record Provided by the NHSTCT Register - 2007 Update - Department of Health0 个研究点目标入组 140 人开始时间: 2007年9月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Stable patients with an established diagnosis of cardiomyopathy as assessed by history, examination and typical ECG/Echo findings who are on maximally tolerated doses of appropriate drugs with no changes being made to the prescription in the 2 months preceding the start of the trial.

排除标准

  • 1. Patients already established on treatment with an aldosterone antagonist
  • 2. Patients with contraindications to eplerenone (hyperkalaemia, renal failure)
  • 3. Critically ill patients requiring respiratory and/or circulatory support
  • 4. Pacemaker or ICD
  • 5. Implanted ferromagnetic cerebrovascular clips
  • 6. Pregnant women (precautionary only)
  • 7. Intolerance of confined spaces
  • 8. Inability to lie supine for 60 minutes
  • 9. Unwilling or unable to give written informed consent
  • 10.Atrial fibrillation or ventricular bigeminy
  • 11. Any contraindication to CMR.
  • 12. Recent MI
  • 13. HCM patients who have received surgical/alcohol ablation treatment

研究者

发起方
Record Provided by the NHSTCT Register - 2007 Update - Department of Health

相似试验